Gennex Labs - Gennex Laboratories Share Price

10.50-0.14 (-1.31%)

BSE

Closed
As On:
As On: 19 Jun, 2026, 03:47 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

STOCK SCORE

Unlock Scores

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	-
High	-
Low	-
Prev Close	-
Volume	-
VWAP(₹)	-

Share Price	Value
Today/Current/Last	-10.50
Previous Day	-10.64

Gennex Labs Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Gennex Labs Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	62.27	42.96	39.30	36.45	44.16
Total Income Growth (%)	44.97	9.30	7.81	-17.45	10.38
Total Expenses	56.53	35.20	32.21	29.61	39.01
Total Expenses Growth (%)	60.59	9.28	8.79	-24.09	16.95
EBIT	5.74	7.76	7.09	6.85	5.15
EBIT Growth (%)	-25.94	9.38	3.58	32.80	-22.55
Profit after Tax (PAT)	4.46	5.24	9.62	5.02	3.07
PAT Growth (%)	-14.87	-45.58	91.85	63.40	-33.89
EBIT Margin (%)	9.22	18.05	18.04	18.78	11.67
Net Profit Margin (%)	7.16	12.19	24.49	13.76	6.95
Basic EPS (₹)	0.16	0.21	0.23	0.22	0.13

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	38.01	30.71	31.37	27.90	26.15
Total Income Growth (%)	23.77	-2.09	12.41	6.71	-4.37
Total Expenses	34.18	25.07	25.58	22.46	23.44
Total Expenses Growth (%)	36.32	-1.99	13.88	-4.16	6.65
EBIT	3.83	5.64	5.79	5.44	2.71
EBIT Growth (%)	-32.02	-2.54	6.37	100.66	-49.49
Profit after Tax (PAT)	2.99	4.45	4.53	4.15	1.50
PAT Growth (%)	-32.73	-1.81	9.25	176.26	-64.32
EBIT Margin (%)	10.09	18.37	18.45	19.50	10.37
Net Profit Margin (%)	7.88	14.49	14.45	14.87	5.74
Basic EPS (₹)	0.13	0.18	0.19	0.18	0.06

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	180.99	148.33	91.62	69.56	62.60
Total Revenue Growth (%)	22.01	61.90	31.72	11.12	4.02
Total Expenses	157.75	126.79	75.13	63.18	57.50
Total Expenses Growth (%)	24.42	68.76	18.91	9.88	5.05
Profit after Tax (PAT)	20.98	18.12	13.18	4.92	3.92
PAT Growth (%)	15.76	37.55	167.74	25.43	-2.85
Operating Profit Margin (%)	15.88	18.24	22.56	11.77	9.75
Net Profit Margin (%)	12.14	13.14	15.19	7.50	6.40
Basic EPS (₹)	0.76	0.80	0.66	0.42	0.33

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	128.00	103.80	71.10	68.50	62.60
Total Revenue Growth (%)	23.31	45.99	3.79	9.44	4.02
Total Expenses	109.76	86.59	56.35	62.49	57.50
Total Expenses Growth (%)	26.76	53.67	-9.83	8.68	5.05
Profit after Tax (PAT)	16.13	14.04	11.80	4.56	3.92
PAT Growth (%)	14.90	18.98	158.78	16.20	-2.85
Operating Profit Margin (%)	17.27	19.87	23.81	11.12	9.75
Net Profit Margin (%)	13.45	14.84	17.66	7.00	6.40
Basic EPS (₹)	0.67	0.62	0.69	0.31	0.33

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 2.43% of its operating revenues towards interest expenses and 4.65% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	348.68	256.04	229.99	132.32	68.03
Total Assets Growth (%)	36.18	11.33	73.82	94.51	15.49
Total Liabilities	115.84	61.45	53.52	45.80	24.21
Total Liabilities Growth (%)	88.52	14.81	16.86	89.17	26.15
Total Equity	232.84	194.59	176.46	86.52	43.82
Total Equity Growth (%)	19.66	10.27	103.97	97.46	10.34
Current Ratio (x)	3.66	4.07	4.01	1.65	1.95
Total Debt to Equity (x)	0.16	0.05	0.03	0.01	0.23
Contingent Liabilities	0.00	-	0.98	0.74	0.74

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	273.82	218.38	205.34	96.22	68.21
Total Assets Growth (%)	25.39	6.35	113.41	41.06	15.45
Total Liabilities	55.70	33.59	34.58	17.20	24.21
Total Liabilities Growth (%)	65.82	-2.86	101.05	-28.95	26.16
Total Equity	218.12	184.80	170.76	79.02	44.00
Total Equity Growth (%)	18.03	8.22	116.10	79.59	10.30
Current Ratio (x)	4.57	6.42	5.45	4.53	1.95
Total Debt to Equity (x)	0.10	0.01	0.00	0.01	0.23
Contingent Liabilities	0.00	0.98	1.96	0.74	0.74

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	-63.65	-10.80	-46.69	23.68	6.64
Net Cash used in Investing Activities	-4.80	0.82	18.91	-38.33	-1.26
Net Cash flow from Financing Activities	65.30	4.57	73.68	21.03	1.87
Net Cash Flow	-3.15	-5.41	45.91	6.38	7.24
Closing Cash & Cash Equivalent	52.42	55.57	60.98	15.06	8.31
Closing Cash & Cash Equivalent Growth (%)	-5.67	-8.87	304.77	81.21	677.53
Total Debt/ CFO (x)	-0.56	-0.95	-0.12	0.04	1.53

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	-40.18	-9.52	-33.43	-14.45	6.64
Net Cash used in Investing Activities	1.62	2.63	0.93	-0.77	-1.26
Net Cash flow from Financing Activities	35.40	1.53	79.01	21.35	1.87
Net Cash Flow	-3.16	-5.36	46.51	6.14	7.24
Closing Cash & Cash Equivalent	52.40	55.60	60.96	14.45	8.31
Closing Cash & Cash Equivalent Growth (%)	-5.75	-8.79	321.84	73.84	677.53
Total Debt/ CFO (x)	-0.57	-0.13	-0.03	-0.07	1.53

All figures in Rs Cr, unless mentioned otherwise

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	9.42	9.70	7.73	6.12	8.95
Return on Capital Employed (%)	9.93	11.89	10.31	7.51	13.62
Return on Assets (%)	6.01	7.07	5.72	3.71	5.76
Interest Coverage Ratio (x)	7.17	7.52	7.13	6.39	7.70
Asset Turnover Ratio (x)	0.57	0.57	0.48	0.65	0.96
Price to Earnings (x)	8.26	15.13	27.32	20.58	24.33
Price to Book (x)	0.78	1.47	2.11	1.26	2.17
EV/EBITDA (x)	5.55	8.72	14.14	10.78	14.36
EBITDA Margin (%)	17.41	19.68	25.29	13.17	11.04

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	7.39	7.59	6.90	5.76	8.91
Return on Capital Employed (%)	9.33	9.93	9.22	9.01	13.57
Return on Assets (%)	5.89	6.42	5.74	4.73	5.75
Interest Coverage Ratio (x)	8.78	12.35	14.47	6.49	7.70
Asset Turnover Ratio (x)	0.49	0.45	0.44	0.79	0.96
Price to Earnings (x)	10.75	19.53	30.49	22.22	24.33
Price to Book (x)	0.79	1.48	2.10	1.28	2.17
EV/EBITDA (x)	6.63	11.23	17.90	10.97	14.36
EBITDA Margin (%)	18.08	20.68	25.03	12.26	11.04

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Gennex Labs	10.48	1.10	9.42	9.93	6.01	37.10	15.88	12.14	0.76	3.66	0.16	-0.56
Medicamen Bio	28.65	1.13	3.49	5.45	2.59	11.78	7.82	4.95	7.22	2.54	0.17	-1.44
Zenotech Lab	-252.47	2.81	-12.98	-10.25	-11.32	1.80	-165.55	-189.76	-3.64	6.42	0.11	-1.03
Everest Org	47.79	3.51	7.34	16.63	2.31	1.27	7.42	2.82	5.70	1.10	0.66	11.94
BDH Industries	23.37	3.28	14.04	19.28	10.91	9.16	15.89	11.26	18.78	4.00	0.03	-0.84
Add More

Annual Ratios (%)

Choose from Peers

Lyka Labs
Ambalal Sarabhai
Aarey Drugs
Nectar Lifesc
Brooks Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Gennex Labs Stock Performance	-1.31	10.41	-1.69	-10.18	-18.10	64.58	62.79
Medicamen Bio Stock Performance	2.34	-16.01	-12.30	-27.69	-47.00	-64.98	-60.74
Zenotech Lab Stock Performance	-4.82	-1.62	-4.71	-4.34	-29.97	-14.91	1.03
Everest Org Stock Performance	0.57	5.20	-2.99	-26.04	-36.81	168.83	-18.62
BDH Industries Stock Performance	0.25	19.74	16.37	1.56	66.55	204.61	339.17
Add More

Category	No. of Shares	Percentage
Promoters	5,74,05,624	23.63 %
Pledge	1,00,00,000	17.42 %
Others	18,55,42,050	76.37 %

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	23.63	23.62	23.62	19.83
Pledge	17.42	17.43	17.43	21.79
FII	0.00	0.00	0.00	0.00
DII	0.00	0.00	0.00	0.00
Mutual Funds	0.00	0.00	0.00	0.00
Others	76.37	76.38	76.38	80.17

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Board Meeting
Audited Results
May 19, 2026
General Meeting
-
Apr 20, 2026
Board Meeting
Others
Apr 08, 2026

Board Meetings

Announced on	Meeting on
May 19, 2026	May 30, 2026
Audited Results
Apr 08, 2026	Apr 16, 2026
Others
Feb 05, 2026	Feb 14, 2026
Quarterly Results
Nov 04, 2025	Nov 14, 2025
Quarterly Results
Aug 26, 2025	Sep 04, 2025
A.G.M.

Dividends
Announced on Ex-Date Dividend%
Jun 26, 2001 - 10%
Bonus
No Data Available
Splits
Announced on Ex-Date
Sep 22, 2009 Dec 14, 2009
Split: Old FV10.0| New FV:1.0
Rights
Announced on Ex-Date
Apr 06, 2022 Jul 21, 2022
Rights ratio: 1 share for every 2 held at a price of Rs 6.0

Announced on	Ex-Date	Dividend%
Jun 26, 2001	-	10%

Announced on	Ex-Date
Sep 22, 2009	Dec 14, 2009
Split: Old FV10.0\| New FV:1.0

Announced on	Ex-Date
Apr 06, 2022	Jul 21, 2022
Rights ratio: 1 share for every 2 held at a price of Rs 6.0

AGM/EGM Meetings

Announced on	Meeting on
Apr 20, 2026	May 12, 2026
-
Sep 15, 2025	Sep 30, 2025
Book closure from Sep 23, 2025 to Sep 30, 2025
Sep 17, 2024	Sep 30, 2024
A.G.M.
Dec 11, 2023	Dec 30, 2023
-
Sep 18, 2023	Sep 30, 2023
A.G.M.

About Gennex Labs

Gennex Laboratories Ltd., incorporated in the year 1990, is a Small Cap company (having a market cap of Rs 255.10 Crore) operating in Pharmaceuticals sector.

Gennex Laboratories Ltd. key Products/Revenue Segments include Bulk Drugs (Intermediates) for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 62.27 Crore, up 44.97 % from last quarter Total Income of Rs 42.96 Crore and up 41.02 % from last year same quarter Total Income of Rs 44.16 Crore. Company has reported net profit after tax of Rs 4.46 Crore in latest quarter.

The company’s top management includes Mr.Arihant Baid, Dr.A R R Pantulu, Mr.Sandeep Kumar Daga, Mr.A S Nageswar Rao, Mr.Dilip Raj Singhvi, Ms.Shilpa Bung, Mr.Akkali Santosh Kumar, Mr.K V L N Bhaswanth, Mr.Dinesh Kumar Kejriwal. Company has R Pugalia & Co. as its auditors. As on 31-03-2026, the company has a total of 24.29 Crore shares outstanding.

Gennex Labs Share Price Today is Rs. 10.50. On previous day, the Gennex Labs Share Price (NSE) closed at Rs. 10.44, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 23.63% of the stake in Gennex Labs shares, out of which 17.42% was pledged. On the same date, foreign institutional investors' (FII) holdings of Gennex Labs stocks was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. Out of the total DII holdings in Gennex Labs shares 0.0% was held by mutual funds. The rest including public held is 0.0%. Gennex Labs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Gennex Labs Dividend: Ever since 1990, Gennex Labs dividends has been paid out around 1 times. As on 19 Jun, 2026, 03:47 PM IST, The overall dividend yield for Gennex Labs stands at 0.0%. The last dividend paid was on null (Rs. null). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 1.0.

Gennex Labs Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 62.27 Cr. of sales and 44.97% of quarterly net profit, there have been multiple ups and downs in the Gennex Labs stock prices in the past few weeks. For example, Gennex Labs stock price on 11th of June 2026 was around Rs. 10.04. Gennex Labs share price now stands at an average of Rs. 10.50. Judging by last week's performance, stock is in up trend.

Gennex Labs has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Gennex Labs share.

Historical Prices and Performance:
Gennex Labs, incorporated in 1990 is a Small Cap company (with a market cap of Rs. 259.23) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Gennex Labs stock was 9.42%, 9.7%, 7.73%, 6.12% and 8.95% respectively.
The Gennex Labs share gave a 3 year return of 55.77% as compared to Nifty 50 which gave a return of 28.38%.
Gennex Labs announced 10.0% final dividend on null.

Key Metrics:
PE Ratio of Gennex Labs is 10.46
Prices/Sales Ratio of Gennex Labs is 1.0
Price/Book Ratio of Gennex Labs is 1.09

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. The PE ratio and PB Ratio of the company are among its competitors stand at 10.46 and 1.09 respectively.

Leadership of Gennex Labs :
Dinesh Kumar Kejriwal is Co. Secretary & Compl. Officer
K V L N Bhaswanth is Chief Operating Officer
Akkali Santosh Kumar is Chief Financial Officer
Arihant Baid is Managing Director
A R R Pantulu is Non Executive Director
Sandeep Kumar Daga is Non Executive Director
A S Nageswar Rao is Independent Director
Dilip Raj Singhvi is Independent Director
Shilpa Bung is Independent Woman Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

Sy. No.133,IDA Bollaram,Sangareddy Dist., Telangana - 502325

Contact

info@gennexlab.com

http://www.gennexlab.com

PE Ratio(x)	10.48
EPS - TTM(₹)	1.00
MCap(₹ Cr.)	255.10
MCap Rank	114
PB Ratio(x)	1.11
Div Yield(%)	-
Face Value(₹)	1.00
52W High(₹)	17.25
52W Low(₹)	7.05
MCap/Sales	1.00
Beta(1 Month)	1.41
BV/Share(₹)	9.58

1 Day	-1.31%
1 Month	-4.11%
3 Months	12.66%
1 Year	-14.08%
3 Years	49.57%
5 Years	54.41%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Gennex Labs - Gennex Laboratories Share Price

Key Metrics

Gennex Labs share price insights

Gennex Labs Share Price Returns

Gennex Labs Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Gennex Labs Top Searches

Corporate Actions

About Gennex Labs

Executive Leadership

Auditors

FAQs about Gennex Labs share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News